315 related articles for article (PubMed ID: 36111783)
1. Propagation of Parkinson's disease by extracellular vesicle production and secretion.
Shippey LE; Campbell SG; Hill AF; Smith DP
Biochem Soc Trans; 2022 Oct; 50(5):1303-1314. PubMed ID: 36111783
[TBL] [Abstract][Full Text] [Related]
2. CSF-derived extracellular vesicles from patients with Parkinson's disease induce symptoms and pathology.
Herman S; Djaldetti R; Mollenhauer B; Offen D
Brain; 2023 Jan; 146(1):209-224. PubMed ID: 35881523
[TBL] [Abstract][Full Text] [Related]
3. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal.
Zhang S; Eitan E; Wu TY; Mattson MP
Neurobiol Aging; 2018 Jan; 61():52-65. PubMed ID: 29035751
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities.
Lööv C; Scherzer CR; Hyman BT; Breakefield XO; Ingelsson M
Cell Mol Neurobiol; 2016 Apr; 36(3):437-48. PubMed ID: 26993503
[TBL] [Abstract][Full Text] [Related]
5. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles contain filamentous alpha-synuclein and facilitate the propagation of Parkinson's pathology.
Ishiguro Y; Tsunnemi T; Shimada T; Yoroisaka A; Ueno SI; Takeshige-Amano H; Hatano T; Inoue Y; Saiki S; Hattori N
Biochem Biophys Res Commun; 2024 Apr; 703():149620. PubMed ID: 38359614
[TBL] [Abstract][Full Text] [Related]
7. Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease.
Chung CC; Chan L; Chen JH; Hung YC; Hong CT
Biomolecules; 2021 May; 11(5):. PubMed ID: 34067663
[TBL] [Abstract][Full Text] [Related]
8. Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?
Matsumoto J; Stewart T; Sheng L; Li N; Bullock K; Song N; Shi M; Banks WA; Zhang J
Acta Neuropathol Commun; 2017 Sep; 5(1):71. PubMed ID: 28903781
[TBL] [Abstract][Full Text] [Related]
9. Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease.
Leggio L; Paternò G; Vivarelli S; L'Episcopo F; Tirolo C; Raciti G; Pappalardo F; Giachino C; Caniglia S; Serapide MF; Marchetti B; Iraci N
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32948090
[TBL] [Abstract][Full Text] [Related]
10. Internalization, axonal transport and release of fibrillar forms of alpha-synuclein.
Bieri G; Gitler AD; Brahic M
Neurobiol Dis; 2018 Jan; 109(Pt B):219-225. PubMed ID: 28323023
[TBL] [Abstract][Full Text] [Related]
11. Potential of extracellular vesicles in the Parkinson's disease - Pathological mediators and biomarkers.
Zhao Y; Yang G
Neurochem Int; 2021 Mar; 144():104974. PubMed ID: 33485881
[TBL] [Abstract][Full Text] [Related]
12. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.
Lee SJ
J Mol Neurosci; 2008; 34(1):17-22. PubMed ID: 18157654
[TBL] [Abstract][Full Text] [Related]
13. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.
Rey NL; George S; Steiner JA; Madaj Z; Luk KC; Trojanowski JQ; Lee VM; Brundin P
Acta Neuropathol; 2018 Jan; 135(1):65-83. PubMed ID: 29209768
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinson's disease.
Liu Z; Chan RB; Cai Z; Liu X; Wu Y; Yu Z; Feng T; Yang Y; Zhang J
J Neuroinflammation; 2022 Feb; 19(1):53. PubMed ID: 35193594
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein-carrying extracellular vesicles in Parkinson's disease: deadly transmitters.
Chistiakov DA; Chistiakov AA
Acta Neurol Belg; 2017 Mar; 117(1):43-51. PubMed ID: 27473175
[TBL] [Abstract][Full Text] [Related]
16. Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease.
Vella LJ; Hill AF; Cheng L
Int J Mol Sci; 2016 Feb; 17(2):173. PubMed ID: 26861304
[TBL] [Abstract][Full Text] [Related]
17. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
18. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
19. Glymphatic System Dysfunction and Sleep Disturbance May Contribute to the Pathogenesis and Progression of Parkinson's Disease.
Scott-Massey A; Boag MK; Magnier A; Bispo DPCF; Khoo TK; Pountney DL
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361716
[TBL] [Abstract][Full Text] [Related]
20. A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology.
Chedid J; Labrador-Garrido A; Zhong S; Gao J; Zhao Y; Perera G; Kim WS; Halliday GM; Dzamko N
J Biol Chem; 2022 Aug; 298(8):102260. PubMed ID: 35841928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
